
About QMS MEDICAL ALLIED SERVICES
QMS MEDICAL ALLIED SERVICES is a publicly listed company based in Mumbai (India) founded in 1994. Online store for medical devices, instruments, and supplies in India. It operates on a B2B and B2C model. The company has 83 employees. Its Indian entity Qms Medical Allied Services Limited reported revenue of βΉ174 Cr. QMS MEDICAL ALLIED SERVICES offers products and services including Littmann Stethoscope, Omron Blood Pressure Monitor, Q Devices Nebulizer, Tynor Heating Gel Pad, and HEINE Sphygmomanometer. Its focus areas include Health, Medical Devices, Distribution and Online Retail. Its competitors include Medikabazaar and Aknamed; 2 of its 2 listed competitors have raised funding.
Company details
Qmsmeds is an online platform based in Mumbai, India, offering a wide range of medical products including devices, instruments, and accessories. It sources from various manufacturers and sells to clinicians, distributors, and individuals through an e-commerce interface. The service includes easy ordering, multiple payment options, and doorstep delivery across the country, ensuring access to quality medical supplies for healthcare professionals.
- Headquarters Mumbai, India
- Employees 83
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website qmsmeds.com
- Social Instagram
- Legal Name Qms Medical Allied Services Limited
- Date of Incorporation 14 Sep, 2017
- Jurisdiction Mumbai, Maharashtra, India
- Market Cap₹329 Cr
QMSMEDI-BE · NSE
- Share Price₹170.01
+0.05% today
- Revenue₹173 Cr
FY 2025-26 · +10.8% YoY
- EBITDA₹26.62 Cr
Margin 15.4%
- Net Profit₹10.07 Cr
FY 2025-26 · -16.6% YoY
- P/E (TTM)33.3x
P/B 3.7x
- ROE12.3%
ROCE 13.9%
- Debt / Equity0.69
Interest cover 29.9x
- Employee Count83
Associated legal entities of QMS MEDICAL ALLIED SERVICES
QMS MEDICAL ALLIED SERVICES operates through Qms Medical Allied Services Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Qms Medical Allied Services Limited Listed CIN L33309MH2017PLC299748 | Active | 14 Sep 2017 | Mumbai, Maharashtra | ₹174 Cr | 83 | 8 | View details |
Products & Services of QMS MEDICAL ALLIED SERVICES
QMS MEDICAL ALLIED SERVICES offers a comprehensive portfolio of products and services, including Littmann Stethoscope, Omron Blood Pressure Monitor, Q Devices Nebulizer, Tynor Heating Gel Pad, and HEINE Sphygmomanometer.
Diagnostic tool for monitoring heart and lung sounds
Digital device for accurate blood pressure measurement
Portable device for respiratory treatments
Therapeutic pad for pain relief and muscle support
Manual device for blood pressure monitoring
Board of directors of Qms Medical Allied Services Limited (QMS MEDICAL ALLIED SERVICES)
Qms Medical Allied Services Limited is the primary company behind QMS MEDICAL ALLIED SERVICES. The board of Qms Medical Allied Services Limited currently have 6 directors; the longest-serving is Mahesh Pahalraj Makhija, appointed in 2017. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mahesh Pahalraj Makhija DIN 02700606 | Managing Director | 14 Sep 2017 | 9 yrs 2 mo | Qms Medical Allied Services Limited |
| Niken Ravin Shah DIN 07604022 | Director | 11 Mar 2022 | 4 yrs 8 mo | Qms Medical Allied Services Limited |
| Prajwal Jayasheela Poojari DIN 07480513 | Director | 15 Jun 2022 | 4 yrs 5 mo | Qms Medical Allied Services Limited |
| Deena Nath Pathak DIN 02104727 | Director | 23 Aug 2024 | 2 yrs 2 mo | Qms Medical Allied Services Limited |
| Sarita Vijay Mahajan DIN 10841279 | Director | 19 Nov 2024 | 1 yr 11 mo | Qms Medical Allied Services Limited |
| Pranav Manhar Badheka DIN 06460764 | Director | 03 Sep 2026 | 2 mo | Qms Medical Allied Services Limited |
IPO & Listings of QMS MEDICAL ALLIED SERVICES
QMS MEDICAL ALLIED SERVICES is a publicly listed company on the NSE with ticker symbol QMSMEDI in India. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: QMSMEDI
- Listed entityQms Medical Allied Services Limited
Financials of QMS MEDICAL ALLIED SERVICES
Exchange-reported figures of Qms Medical Allied Services Limited, the listed company behind QMS MEDICAL ALLIED SERVICES (NSE: QMSMEDI-BE).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 173 | 156 | 122 |
| Revenue growth | +10.8% | +27.7% | - |
| EBITDA | 26.62 | 25.40 | 18.34 |
| EBITDA margin | +15.4% | +16.3% | +15.0% |
| Profit before tax | 16.38 | 18.65 | 12.23 |
| Net profit | 10.07 | 12.07 | 9.00 |
| Net profit margin | +5.8% | +7.7% | +7.4% |
| EPS (βΉ) | 6.32 | 6.77 | 5.04 |
| Balance sheet | |||
| Total assets | 189 | 168 | 113 |
| Net worth | 104 | 89.71 | 78.51 |
| Total debt | 74.48 | 60.28 | 34.54 |
| Cash & bank | 1.20 | 1.07 | 0.31 |
| Net working capital | 113 | 94.52 | 81.88 |
| Cash flow | |||
| Cash from operations | 19.44 | 19.17 | 1.36 |
| Cash from investing | (20.42) | (45.49) | (2.73) |
| Cash from financing | 1.11 | 26.84 | 0.41 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 52.52 | 56.87 | 44.42 | 37.26 | 44.70 | 46.50 | 44.58 | 43.87 |
| Revenue growth (YoY) | +17.5% | +22.3% | -0.4% | -15.1% | +20.2% | +53.1% | - | - |
| Other income | 0.22 | 0.42 | 0.22 | 0.30 | 0.22 | 0.32 | 1.09 | 0.19 |
| EBITDA | 6.52 | 8.31 | 5.91 | 6.75 | 6.92 | 6.54 | 6.37 | 6.95 |
| EBITDA margin | +12.4% | +14.6% | +13.3% | +18.1% | +15.5% | +14.1% | +14.3% | +15.8% |
| Depreciation | 1.60 | 1.47 | 1.39 | 1.02 | 0.94 | 0.93 | 1.36 | 0.86 |
| Interest | 1.86 | 1.71 | 2.08 | 1.75 | 1.36 | 1.44 | 1.41 | 1.31 |
| Profit before tax | 3.28 | 5.55 | 2.66 | 4.28 | 4.84 | 4.49 | 4.69 | 4.97 |
| Tax | 0.84 | 1.59 | 0.78 | 1.10 | 1.27 | 1.33 | 1.09 | 1.50 |
| Net profit | 2.44 | 3.96 | 1.88 | 3.18 | 3.57 | 3.16 | 3.60 | 3.47 |
| EPS (βΉ) | 1.26 | 2.05 | 0.97 | 1.24 | 1.71 | 2.20 | 1.87 | 1.63 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 152 | 145 | 122 | 104 | 146 | 122 | 72.74 |
| Revenue growth | +5.1% | +18.6% | +17.4% | -28.9% | +19.9% | +67.8% | - |
| EBITDA | 21.08 | 23.33 | 18.34 | 11.33 | 16.64 | 16.99 | 9.60 |
| EBITDA margin | +13.8% | +16.1% | +15.0% | +10.9% | +11.4% | +13.9% | +13.2% |
| Profit before tax | 9.31 | 14.43 | 12.23 | 8.71 | 14.46 | 14.90 | 8.72 |
| Net profit | 6.59 | 10.42 | 9.00 | 6.38 | 9.69 | 10.91 | 6.32 |
| Net profit margin | +4.3% | +7.2% | +7.4% | +6.1% | +6.6% | +8.9% | +8.7% |
| EPS (βΉ) | 3.51 | 5.84 | 5.04 | 3.57 | 28.40 | 29.02 | 21.00 |
| Balance sheet | |||||||
| Total assets | 196 | 166 | 113 | 96.01 | 63.01 | 39.93 | 21.01 |
| Net worth | 104 | 88.04 | 78.51 | 70.40 | 31.03 | 20.32 | 9.41 |
| Total debt | 90.92 | 77.25 | 2.37 | 25.52 | 31.97 | 19.60 | 11.60 |
| Cash & bank | 0.11 | 0.39 | 0.31 | 2.37 | 2.16 | 1.38 | 0.66 |
| Net working capital | 103 | 88.08 | 81.88 | 65.60 | 54.85 | 29.40 | 17.58 |
| Cash flow | |||||||
| Cash from operations | 18.77 | 26.09 | 1.36 | (7.54) | (1.72) | 1.88 | 4.18 |
| Cash from investing | (18.27) | (48.90) | (1.78) | (25.10) | 2.37 | (7.84) | (3.66) |
| Cash from financing | (0.78) | 22.88 | (1.07) | 31.74 | 0.13 | 6.69 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.94 | 52.34 | 39.19 | 29.54 | 41.25 | 42.32 | 42.38 | 39.38 |
| Revenue growth (YoY) | +23.5% | +23.7% | -7.5% | -25.0% | +26.0% | +39.4% | - | - |
| Other income | 0.08 | 0.25 | 0.07 | 0.13 | 0.00 | 0.15 | 0.13 | 0.12 |
| Total expenses | 44.65 | 45.34 | 34.81 | 25.77 | 35.12 | 35.99 | 34.56 | 34.05 |
| EBITDA | 6.29 | 7.00 | 4.38 | 3.77 | 6.13 | 6.33 | 7.82 | 5.33 |
| EBITDA margin | +12.3% | +13.4% | +11.2% | +12.8% | +14.9% | +15.0% | +18.5% | +13.5% |
| Depreciation | 1.43 | 1.31 | 1.22 | 0.92 | 0.83 | 0.83 | 0.90 | 0.91 |
| Interest | 2.21 | 2.05 | 2.38 | 2.06 | 1.73 | 1.77 | 2.73 | 1.31 |
| Profit before tax | 2.73 | 3.89 | 0.85 | 0.92 | 3.57 | 3.88 | 4.32 | 3.23 |
| Tax | 0.69 | 1.22 | 0.24 | 0.34 | 0.93 | 1.20 | 1.26 | 0.89 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 52.52 | 56.87 | 44.42 | 37.26 | 44.70 | 46.50 | 44.58 | 43.87 |
| Revenue growth (YoY) | +17.5% | +22.3% | -0.4% | -15.1% | +20.2% | +53.1% | - | - |
| Other income | 0.22 | 0.42 | 0.22 | 0.30 | 0.22 | 0.32 | 1.09 | 0.19 |
| EBITDA | 6.52 | 8.31 | 5.91 | 6.75 | 6.92 | 6.54 | 6.37 | 6.95 |
| EBITDA margin | +12.4% | +14.6% | +13.3% | +18.1% | +15.5% | +14.1% | +14.3% | +15.8% |
| Depreciation | 1.60 | 1.47 | 1.39 | 1.02 | 0.94 | 0.93 | 1.36 | 0.86 |
| Interest | 1.86 | 1.71 | 2.08 | 1.75 | 1.36 | 1.44 | 1.41 | 1.31 |
| Profit before tax | 3.28 | 5.55 | 2.66 | 4.28 | 4.84 | 4.49 | 4.69 | 4.97 |
| Tax | 0.84 | 1.59 | 0.78 | 1.10 | 1.27 | 1.33 | 1.09 | 1.50 |
| Net profit | 2.44 | 3.96 | 1.88 | 3.18 | 3.57 | 3.16 | 3.60 | 3.47 |
| EPS (βΉ) | 1.26 | 2.05 | 0.97 | 1.24 | 1.71 | 2.20 | 1.87 | 1.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 173 | 156 | 122 |
| Revenue growth | +10.8% | +27.7% | - |
| Other income | 1.06 | 1.72 | 0.46 |
| Total expenses | 146 | 131 | 104 |
| Employee cost | 0.00 | 7.54 | 3.67 |
| EBITDA | 26.62 | 25.40 | 18.34 |
| EBITDA margin | +15.4% | +16.3% | +15.0% |
| Depreciation | 4.61 | 3.83 | 3.44 |
| Interest | 6.69 | 4.64 | 3.13 |
| Profit before tax | 16.38 | 18.65 | 12.23 |
| Tax | 4.51 | 4.96 | 3.23 |
| Net profit | 10.07 | 12.07 | 9.00 |
| Net profit margin | +5.8% | +7.7% | +7.4% |
| EPS (βΉ) | 6.32 | 6.77 | 5.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 19.34 | 17.85 | 17.85 |
| Reserves & surplus | 84.86 | 71.86 | 60.66 |
| Shareholders' funds (net worth) | 104 | 89.71 | 78.51 |
| Minority interest | 9.77 | 17.39 | 0.00 |
| Secured loans | 69.01 | 54.82 | 33.46 |
| Unsecured loans | 5.47 | 5.46 | 1.08 |
| Total debt | 74.48 | 60.28 | 34.54 |
| Total liabilities | 189 | 168 | 113 |
| Assets | |||
| Gross block | 72.25 | 66.21 | 30.03 |
| Net block | 54.62 | 52.42 | 23.58 |
| Capital work in progress | 2.83 | 3.19 | 2.06 |
| Investments | 5.46 | 3.23 | 2.11 |
| Inventories | 45.92 | 39.33 | 37.58 |
| Sundry debtors | 67.32 | 57.93 | 41.39 |
| Cash & bank balances | 1.20 | 1.07 | 0.31 |
| Loans & advances | 22.12 | 18.48 | 24.39 |
| Total current assets | 137 | 117 | 104 |
| Total current liabilities | 23.75 | 22.29 | 21.79 |
| Net working capital | 113 | 94.52 | 81.88 |
| Total assets | 189 | 168 | 113 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 1.06 | 0.31 | 1.27 |
| Net cash from operating activities | 19.44 | 19.17 | 1.36 |
| Net cash from investing activities | (20.42) | (45.49) | (2.73) |
| Net cash from financing activities | 1.11 | 26.84 | 0.41 |
| Net change in cash | 0.13 | 0.52 | (0.96) |
| Closing cash | 1.20 | 1.07 | 0.31 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +10.8% | +27.7% | - |
| EBITDA growth | +4.8% | +38.5% | - |
| PBT growth | -11.9% | +52.6% | +9997.0% |
| Net income growth | -16.6% | +34.1% | - |
| Profitability & leverage | |||
| Net income margin | +6.9% | +8.8% | +7.4% |
| Return on capital employed | +14.0% | +17.7% | +13.6% |
| Return on net worth | +12.3% | +16.3% | +11.5% |
| Debt / equity | 0.69 | 0.56 | 0.44 |
| Long-term debt / equity | 0.08 | 0.07 | 0.03 |
| Interest cover | 29.85 | 21.50 | 21.01 |
| Efficiency & per share | |||
| Fixed asset turnover | 2.50 | 3.24 | 4.07 |
| Inventory turnover | 4.06 | 4.06 | 3.25 |
| Debtors turnover | 2.76 | 3.14 | 2.95 |
| EPS (βΉ) | 5.24 | 6.77 | 5.04 |
| Dividend per share (βΉ) | 0.50 | 0.50 | 0.00 |
| Book value per share (βΉ) | 53.88 | 50.26 | 43.99 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.94 | 52.34 | 39.19 | 29.54 | 41.25 | 42.32 | 42.38 | 39.38 |
| Revenue growth (YoY) | +23.5% | +23.7% | -7.5% | -25.0% | +26.0% | +39.4% | - | - |
| Other income | 0.08 | 0.25 | 0.07 | 0.13 | 0.00 | 0.15 | 0.13 | 0.12 |
| Total expenses | 44.65 | 45.34 | 34.81 | 25.77 | 35.12 | 35.99 | 34.56 | 34.05 |
| EBITDA | 6.29 | 7.00 | 4.38 | 3.77 | 6.13 | 6.33 | 7.82 | 5.33 |
| EBITDA margin | +12.3% | +13.4% | +11.2% | +12.8% | +14.9% | +15.0% | +18.5% | +13.5% |
| Depreciation | 1.43 | 1.31 | 1.22 | 0.92 | 0.83 | 0.83 | 0.90 | 0.91 |
| Interest | 2.21 | 2.05 | 2.38 | 2.06 | 1.73 | 1.77 | 2.73 | 1.31 |
| Profit before tax | 2.73 | 3.89 | 0.85 | 0.92 | 3.57 | 3.88 | 4.32 | 3.23 |
| Tax | 0.69 | 1.22 | 0.24 | 0.34 | 0.93 | 1.20 | 1.26 | 0.89 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 152 | 145 | 122 | 104 | 146 | 122 | 72.74 |
| Revenue growth | +5.1% | +18.6% | +17.4% | -28.9% | +19.9% | +67.8% | - |
| Other income | 0.36 | 0.46 | 0.46 | 0.74 | 1.42 | 0.06 | 0.04 |
| Total expenses | 131 | 122 | 104 | 92.71 | 130 | 105 | 63.14 |
| Employee cost | 0.00 | 6.00 | 3.67 | 2.61 | 3.83 | 1.56 | 0.92 |
| EBITDA | 21.08 | 23.33 | 18.34 | 11.33 | 16.64 | 16.99 | 9.60 |
| EBITDA margin | +13.8% | +16.1% | +15.0% | +10.9% | +11.4% | +13.9% | +13.2% |
| Depreciation | 4.12 | 3.40 | 3.44 | 1.07 | 1.16 | 0.74 | 0.36 |
| Interest | 8.01 | 5.96 | 3.13 | 2.29 | 2.44 | 1.41 | 0.56 |
| Profit before tax | 9.31 | 14.43 | 12.23 | 8.71 | 14.46 | 14.90 | 8.72 |
| Tax | 2.72 | 4.00 | 3.23 | 2.33 | 3.77 | 3.99 | 2.40 |
| Net profit | 6.59 | 10.42 | 9.00 | 6.38 | 9.69 | 10.91 | 6.32 |
| Net profit margin | +4.3% | +7.2% | +7.4% | +6.1% | +6.6% | +8.9% | +8.7% |
| EPS (βΉ) | 3.51 | 5.84 | 5.04 | 3.57 | 28.40 | 29.02 | 21.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 19.34 | 17.85 | 17.85 | 17.85 | 3.76 | 3.76 | 3.01 |
| Reserves & surplus | 84.88 | 70.19 | 60.66 | 52.55 | 27.27 | 16.56 | 6.40 |
| Shareholders' funds (net worth) | 104 | 88.04 | 78.51 | 70.40 | 31.03 | 20.32 | 9.41 |
| Secured loans | 85.45 | 71.79 | 0.00 | 25.52 | 31.38 | 18.05 | 8.99 |
| Unsecured loans | 5.47 | 5.46 | 2.37 | 0.00 | 0.59 | 1.55 | 2.61 |
| Total debt | 90.92 | 77.25 | 2.37 | 25.52 | 31.97 | 19.60 | 11.60 |
| Total liabilities | 196 | 166 | 113 | 96.01 | 63.01 | 39.93 | 21.01 |
| Assets | |||||||
| Gross block | 37.90 | 32.07 | 30.03 | 28.37 | 9.91 | 11.30 | 3.63 |
| Net block | 24.65 | 22.33 | 23.58 | 25.36 | 7.97 | 10.17 | 3.24 |
| Capital work in progress | 2.64 | 2.93 | 2.06 | 1.15 | 0.00 | 0.00 | 0.00 |
| Investments | 63.09 | 48.33 | 2.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 45.92 | 39.28 | 37.58 | 29.93 | 24.25 | 20.31 | 15.69 |
| Sundry debtors | 59.17 | 53.82 | 41.39 | 39.04 | 42.04 | 22.98 | 11.21 |
| Cash & bank balances | 0.11 | 0.39 | 0.31 | 2.37 | 2.16 | 1.38 | 0.66 |
| Loans & advances | 22.19 | 17.99 | 24.39 | 15.59 | 5.62 | 5.12 | 2.49 |
| Total current assets | 127 | 111 | 104 | 86.93 | 74.07 | 49.79 | 30.05 |
| Total current liabilities | 24.24 | 23.40 | 21.79 | 21.33 | 19.22 | 20.39 | 12.47 |
| Net working capital | 103 | 88.08 | 81.88 | 65.60 | 54.85 | 29.40 | 17.58 |
| Total assets | 196 | 166 | 113 | 96.01 | 63.01 | 39.93 | 21.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.38 | 0.31 | 1.27 | 2.16 | 1.38 | 0.66 | 0.14 |
| Net cash from operating activities | 18.77 | 26.09 | 1.36 | (7.54) | (1.72) | 1.88 | 4.18 |
| Net cash from investing activities | (18.27) | (48.90) | (1.78) | (25.10) | 2.37 | (7.84) | (3.66) |
| Net cash from financing activities | (0.78) | 22.88 | (1.07) | 31.74 | 0.13 | 6.69 | 0.00 |
| Net change in cash | (0.28) | 0.07 | (1.48) | (0.90) | 0.78 | 0.73 | 0.52 |
| Closing cash | 0.11 | 0.39 | 0.31 | 2.37 | 2.16 | 1.38 | 0.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +5.1% | +18.6% | +17.4% | -28.9% | +19.9% | +67.8% | - |
| EBITDA growth | -9.6% | +27.2% | +61.9% | -31.9% | -2.1% | +77.0% | - |
| PBT growth | -34.5% | +17.9% | +40.4% | -39.8% | -3.0% | +70.9% | +99.1% |
| Net income growth | -36.8% | +15.8% | +41.1% | -34.2% | -11.2% | +72.6% | - |
| Revenue CAGR (3Y) | +13.5% | -0.3% | +0.0% | +12.7% | +41.3% | +1051.1% | - |
| EBITDA CAGR (3Y) | +21.9% | +11.9% | +2.6% | +5.7% | +52.9% | +1093.3% | - |
| Profitability & leverage | |||||||
| Net income margin | +4.4% | +7.2% | +7.4% | +6.1% | +7.3% | +8.9% | +8.7% |
| Return on capital employed | +9.6% | +14.6% | +14.7% | +13.8% | +32.8% | +53.6% | +64.8% |
| Return on net worth | +7.0% | +12.5% | +12.1% | +12.6% | +41.6% | +73.5% | +101.2% |
| Debt / equity | 0.87 | 0.48 | 0.19 | 0.57 | 1.00 | 1.05 | 1.29 |
| Long-term debt / equity | 0.26 | 0.17 | 0.03 | 0.03 | 0.04 | 0.00 | 0.00 |
| Interest cover | 46.44 | 29.92 | 21.01 | 22.32 | 15.76 | 8.68 | 6.06 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 4.35 | 4.67 | 4.18 | 5.44 | 13.80 | 16.35 | 38.49 |
| Inventory turnover | 3.58 | 3.77 | 3.62 | 3.84 | 6.57 | 6.78 | 5.90 |
| Debtors turnover | 2.70 | 3.04 | 3.04 | 2.57 | 4.50 | 7.14 | 7.57 |
| EPS (βΉ) | 3.46 | 5.84 | 5.04 | 3.57 | 28.40 | 29.02 | 21.00 |
| Dividend per share (βΉ) | 0.50 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 53.89 | 49.32 | 43.99 | 39.44 | 82.48 | 54.02 | 31.25 |
Competitors of QMS MEDICAL ALLIED SERVICES
QMS MEDICAL ALLIED SERVICES has 2 listed competitors in our database, 2 of them funded. They include Medikabazaar and Aknamed.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medikabazaar.com | 2014 | Mumbai, India | $184.89M | 547 | Online marketplace for medical supplies, equipment, and devices catering to healthcare providers | |
| aknamed.com | 2018 | Gurugram, India | $21.85M | 246 | Cloud and AI-based material management software for hospitals is offered. |
Detailed competitors of QMS MEDICAL ALLIED SERVICES
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Qms Medical Allied Services
Complete news archive for QMS MEDICAL ALLIED SERVICES
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QMS MEDICAL ALLIED SERVICES
QMS MEDICAL ALLIED SERVICES was founded in 1994.
QMS MEDICAL ALLIED SERVICES is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
QMS MEDICAL ALLIED SERVICES has 83 employees.
The primary company behind QMS MEDICAL ALLIED SERVICES, Qms Medical Allied Services Limited, reported revenue of βΉ174 Cr for FY 2026, up 11% year on year.
Qmsmeds is an online platform based in Mumbai, India, offering a wide range of medical products including devices, instruments, and accessories. It sources from various manufacturers and sells to clinicians, distributors, and individuals through an e-commerce interface. The service includes easy ordering, multiple payment options, and doorstep delivery across the country, ensuring access to quality medical supplies for healthcare professionals.
QMS MEDICAL ALLIED SERVICES's top competitors include Medikabazaar and Aknamed.
QMS MEDICAL ALLIED SERVICES offers Littmann Stethoscope, Omron Blood Pressure Monitor, Q Devices Nebulizer, Tynor Heating Gel Pad, and HEINE Sphygmomanometer.
Yes, QMS MEDICAL ALLIED SERVICES is publicly traded on NSE under the ticker symbol QMSMEDI.
QMS MEDICAL ALLIED SERVICES operates through Qms Medical Allied Services Limited.
The legal entities of QMS MEDICAL ALLIED SERVICES currently have 8 directors, including Prajwal Jayasheela Poojari, Niken Ravin Shah, Mahesh Pahalraj Makhija and others.
